Global report warns of escalating cancer rate

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

A coalition of international cancer experts is warning that the global cancer burden will double over the next two decades with an increasing concentration of cases in low-income and middle-income countries.

A coalition of international cancer experts is warning that the global cancer burden will double over the next two decades with an increasing concentration of cases in low-income and middle-income countries.

The Cancer Treatment Informal Working Group (CanTreat International) released a new report, "The Hidden Epidemic: Women's Cancers in Low- and Middle-Income Countries," at ECCO/ESMO 2009 (abstract 31).

More than half of the 12.4 million estimated new cases of cancer, and two-thirds of the estimated 7.6 million cancer deaths in 2008, occurred in developing countries, where cancer kills more people each year than AIDS, tuberculosis, and malaria, according to the CanTreat International report.

The document also highlights growing incidence of breast cancer and cervical cancer in middle-income Eastern Europe and Russia. Copies of the report are available at www.axios-group.com.

Recent Videos
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.